Clear coverage of hospitals, insurance, pharma, and Washington.
3 stories in this section
Greater insight into PBM revenue streams and rebate arrangements will give employer plan sponsors critical leverage to negotiate pharmacy contracts and satisfy their federal fiduciary obligations.
Clarifying the regulatory framework for customized therapies reduces development uncertainty for biopharma companies, paving the way for scalable investment in ultra-rare, individualized genetic medicines.
A rising profile for Kennedy's MAHA agenda could pressure federal regulators to overhaul food and drug oversight, while impending outbound investment rules risk disrupting cross-border biotech financing and drug development pipelines.